PMID- 26865517
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20220408
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 86
IP  - 10
DP  - 2016 Mar 8
TI  - Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the 
      randomized TEMSO study.
PG  - 920-30
LID - 10.1212/WNL.0000000000002441 [doi]
AB  - OBJECTIVE: To report safety and efficacy outcomes from up to 9 years of treatment 
      with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 
      Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). METHODS: A 
      total of 742 patients entered the extension. Teriflunomide-treated patients 
      continued the original dose; those previously receiving placebo were randomized 
      1:1 to teriflunomide 14 mg or 7 mg. RESULTS: By June 2013, median (maximum) 
      teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) 
      remained on treatment. Teriflunomide was well-tolerated with continued exposure. 
      The most common adverse events (AEs) matched those in the core study. In 
      extension year 1, first AEs of transient liver enzyme increases or reversible 
      hair thinning were generally attributable to patients switching from placebo to 
      teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. 
      Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated 
      to teriflunomide. Soon after the extension started, annualized relapse rates and 
      gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to 
      teriflunomide, remaining low thereafter. Disability remained stable in all 
      treatment groups (median Expanded Disability Status Scale score </=2.5; probability 
      of 12-week disability progression </=0.48). CONCLUSIONS: In the TEMSO extension, 
      safety observations were consistent with the core trial, with no new or 
      unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease 
      activity decreased in patients switching from placebo and remained low in 
      patients continuing on teriflunomide. CLASSIFICATION OF EVIDENCE: This study 
      provides Class III evidence that long-term treatment with teriflunomide is 
      well-tolerated and efficacy of teriflunomide is maintained long-term.
CI  - (c) 2016 American Academy of Neurology.
FAU - O'Connor, Paul
AU  - O'Connor P
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.). opaul362@gmail.com.
FAU - Comi, Giancarlo
AU  - Comi G
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Freedman, Mark S
AU  - Freedman MS
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Miller, Aaron E
AU  - Miller AE
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Kappos, Ludwig
AU  - Kappos L
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Bouchard, Jean-Pierre
AU  - Bouchard JP
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Lebrun-Frenay, Christine
AU  - Lebrun-Frenay C
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Mares, Jan
AU  - Mares J
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Benamor, Myriam
AU  - Benamor M
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Thangavelu, Karthinathan
AU  - Thangavelu K
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Liang, Jinjun
AU  - Liang J
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Truffinet, Philippe
AU  - Truffinet P
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Lawson, Victoria J
AU  - Lawson VJ
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
FAU - Wolinsky, Jerry S
AU  - Wolinsky JS
AD  - From the University of Toronto (P.O.), Ontario, Canada; University Vita-Salute 
      San Raffaele (G.C.), Milan, Italy; University of Ottawa and the Ottawa Hospital 
      Research Institute (M.S.F.), Ontario, Canada; Icahn School of Medicine at Mount 
      Sinai (A.E.M.), New York, NY; University Hospital Basel (L.K.), Switzerland; 
      Laval University, Centre Hospitalier Universitaire de Quebec (J.-P.B.), Quebec, 
      Canada; Hopital Pasteur (C.L.-F.), Nice, France; Fakultni Nemocnice Olomouc 
      (J.M.), Olomouc, Czech Republic; Sanofi Genzyme (M.B., P.T.), Chilly-Mazarin, 
      France; Sanofi Genzyme (K.T.), Cambridge, MA; Sanofi (J.L.), Bridgewater, NJ; 
      Fishawack Communications Ltd. (V.J.L.), Abingdon, UK; and University of Texas 
      Health Science Center at Houston (J.S.W.).
CN  - Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in 
      Houston, Texas
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160210
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Crotonates)
RN  - 0 (Hydroxybutyrates)
RN  - 0 (Nitriles)
RN  - 0 (Toluidines)
RN  - 1C058IKG3B (teriflunomide)
SB  - IM
EIN - Neurology. 2016 Oct 4;87(14 ):1524. PMID: 27698155
MH  - Administration, Oral
MH  - Adult
MH  - Chemical and Drug Induced Liver Injury/diagnosis
MH  - Crotonates/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxybutyrates
MH  - *Internationality
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*diagnosis/*drug therapy/epidemiology
MH  - Nitriles
MH  - Time Factors
MH  - Toluidines/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC4782117
FIR - Maida, E
IR  - Maida E
FIR - Auff, E
IR  - Auff E
FIR - Fazekas, F
IR  - Fazekas F
FIR - Berger, T
IR  - Berger T
FIR - Bhan, V
IR  - Bhan V
FIR - Bouchard, J-P
IR  - Bouchard JP
FIR - Duquette, P
IR  - Duquette P
FIR - Freedman, M
IR  - Freedman M
FIR - Grand'maison, F
IR  - Grand'maison F
FIR - Kremenchutzky, M
IR  - Kremenchutzky M
FIR - Bourque, C
IR  - Bourque C
FIR - Marrie, R A
IR  - Marrie RA
FIR - Melanson, M
IR  - Melanson M
FIR - Patry, D
IR  - Patry D
FIR - O'Connor, P
IR  - O'Connor P
FIR - Oger, J
IR  - Oger J
FIR - Stefanelli, M
IR  - Stefanelli M
FIR - Jacques, F
IR  - Jacques F
FIR - Venegas, P
IR  - Venegas P
FIR - Miranda, M
IR  - Miranda M
FIR - Barrientos, N
IR  - Barrientos N
FIR - Tenhamm, E
IR  - Tenhamm E
FIR - Gloger, S
IR  - Gloger S
FIR - Rohde, G
IR  - Rohde G
FIR - Mares, J
IR  - Mares J
FIR - Frederiksen, J
IR  - Frederiksen J
FIR - Stenager, E
IR  - Stenager E
FIR - Haldre, S
IR  - Haldre S
FIR - Gross-Paju, K
IR  - Gross-Paju K
FIR - Elovaara, I
IR  - Elovaara I
FIR - Sumelahti, M-L
IR  - Sumelahti ML
FIR - Eralinna, J-P
IR  - Eralinna JP
FIR - Eralinna, J-P
IR  - Eralinna JP
FIR - Farkkila, M
IR  - Farkkila M
FIR - Harno, H
IR  - Harno H
FIR - Reunanen, M
IR  - Reunanen M
FIR - Jolma, T
IR  - Jolma T
FIR - Confavreux, C
IR  - Confavreux C
FIR - Camu, W
IR  - Camu W
FIR - Clavelou, P
IR  - Clavelou P
FIR - Magy, L
IR  - Magy L
FIR - Debouverie, M
IR  - Debouverie M
FIR - Edan, G
IR  - Edan G
FIR - Lebrun-Frenay, C
IR  - Lebrun-Frenay C
FIR - Moreau, T
IR  - Moreau T
FIR - Pelletier, J
IR  - Pelletier J
FIR - Roullet, E
IR  - Roullet E
FIR - Alamowitch, S
IR  - Alamowitch S
FIR - Clanet, M
IR  - Clanet M
FIR - Hautecoeur, P
IR  - Hautecoeur P
FIR - Damier, P
IR  - Damier P
FIR - Rumbach, L
IR  - Rumbach L
FIR - Chan, A
IR  - Chan A
FIR - Schimrigk, S
IR  - Schimrigk S
FIR - Haas, J
IR  - Haas J
FIR - Lensch, E
IR  - Lensch E
FIR - Diener, H
IR  - Diener H
FIR - Limmroth, V
IR  - Limmroth V
FIR - Anders, D
IR  - Anders D
FIR - Berghoff, M
IR  - Berghoff M
FIR - Oschmann, P
IR  - Oschmann P
FIR - Stangel, M
IR  - Stangel M
FIR - Berghoff, M
IR  - Berghoff M
FIR - Frese, A
IR  - Frese A
FIR - Kiefer, R
IR  - Kiefer R
FIR - Marziniak, M
IR  - Marziniak M
FIR - Zettl, U
IR  - Zettl U
FIR - Stark, E
IR  - Stark E
FIR - Jendroska, K
IR  - Jendroska K
FIR - Reifschneider, G
IR  - Reifschneider G
FIR - Amato, M P
IR  - Amato MP
FIR - Comi, G
IR  - Comi G
FIR - Cosi, V
IR  - Cosi V
FIR - Gallo, P
IR  - Gallo P
FIR - Gasperini, C
IR  - Gasperini C
FIR - Ghezzi, A
IR  - Ghezzi A
FIR - Trojano, M
IR  - Trojano M
FIR - Pozzilli, C
IR  - Pozzilli C
FIR - Montanari, E
IR  - Montanari E
FIR - Zwanikken, C P
IR  - Zwanikken CP
FIR - Jongen, P J H
IR  - Jongen PJ
FIR - Munster, E Th L Van
IR  - Munster ET
FIR - Hupperts, R M M
IR  - Hupperts RM
FIR - Anten, B
IR  - Anten B
FIR - Sanders, E A C M
IR  - Sanders EA
FIR - Celius, E
IR  - Celius E
FIR - Hovdal, H
IR  - Hovdal H
FIR - Krogseth, S Bohne
IR  - Krogseth SB
FIR - Kozubski, W
IR  - Kozubski W
FIR - Kwiecinski, H
IR  - Kwiecinski H
FIR - Czlonkowska, A
IR  - Czlonkowska A
FIR - Stelmasiak, Z
IR  - Stelmasiak Z
FIR - Selmaj, K
IR  - Selmaj K
FIR - Hasiec, T
IR  - Hasiec T
FIR - Fryze, W
IR  - Fryze W
FIR - Drozdowski, W
IR  - Drozdowski W
FIR - Kochanowicz, J
IR  - Kochanowicz J
FIR - Cunha, L
IR  - Cunha L
FIR - De Sa, J
IR  - De Sa J
FIR - Harrington Sena, A
IR  - Harrington Sena A
FIR - Odinak, M
IR  - Odinak M
FIR - Skoromets, A
IR  - Skoromets A
FIR - Gusev, E
IR  - Gusev E
FIR - Boiko, A
IR  - Boiko A
FIR - Lashch, N
IR  - Lashch N
FIR - Stolyarov, I
IR  - Stolyarov I
FIR - Belova, A
IR  - Belova A
FIR - Malkova, N
IR  - Malkova N
FIR - Doronin, B
IR  - Doronin B
FIR - Yakupov, E
IR  - Yakupov E
FIR - Brundin, L
IR  - Brundin L
FIR - Hillert, J
IR  - Hillert J
FIR - Kappos, L
IR  - Kappos L
FIR - Karabudak, R
IR  - Karabudak R
FIR - Irkec, C
IR  - Irkec C
FIR - Idiman, E
IR  - Idiman E
FIR - Turan, O
IR  - Turan O
FIR - Efendi, H
IR  - Efendi H
FIR - Gedizlioglu, M
IR  - Gedizlioglu M
FIR - Buchakchyyska, N
IR  - Buchakchyyska N
FIR - Goloborodko, A
IR  - Goloborodko A
FIR - Ipatov, A
IR  - Ipatov A
FIR - Kobets, S
IR  - Kobets S
FIR - Lebedynets, V
IR  - Lebedynets V
FIR - Moskovko, S
IR  - Moskovko S
FIR - Sanotskyy, Y
IR  - Sanotskyy Y
FIR - Smolanka, V
IR  - Smolanka V
FIR - Yavorskaya, V
IR  - Yavorskaya V
FIR - Bates, D
IR  - Bates D
FIR - Evangelou, N
IR  - Evangelou N
FIR - Hawkins, C
IR  - Hawkins C
FIR - McLean, B
IR  - McLean B
FIR - O'Riordan, J
IR  - O'Riordan J
FIR - Price, S
IR  - Price S
FIR - Turner, B
IR  - Turner B
FIR - Barnes, D
IR  - Barnes D
FIR - Zajicek, J
IR  - Zajicek J
FIR - Honeycutt, W
IR  - Honeycutt W
FIR - Khan, O
IR  - Khan O
FIR - Spikol, L
IR  - Spikol L
FIR - Stevens, J
IR  - Stevens J
FIR - Narayana, P A
IR  - Narayana PA
FIR - Nelson, F
IR  - Nelson F
FIR - Datta, S
IR  - Datta S
FIR - Vainrub, I
IR  - Vainrub I
FIR - Carrico, B
IR  - Carrico B
FIR - Ton, K
IR  - Ton K
FIR - Brokhin, R
IR  - Brokhin R
FIR - Lambert, L
IR  - Lambert L
EDAT- 2016/02/13 06:00
MHDA- 2016/07/29 06:00
PMCR- 2016/03/08
CRDT- 2016/02/12 06:00
PHST- 2015/03/27 00:00 [received]
PHST- 2015/11/16 00:00 [accepted]
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
PHST- 2016/03/08 00:00 [pmc-release]
AID - WNL.0000000000002441 [pii]
AID - NEUROLOGY2015657304 [pii]
AID - 10.1212/WNL.0000000000002441 [doi]
PST - ppublish
SO  - Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 
      Feb 10.